Divis Laboratories Ltd
₹10037.50
-26.50 (0.26%)
Fri, 06 Nov 2026, 10:05 pm
Health Technology
Pharmaceuticals: Major
24.5KDivis Laboratories Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 35.17 | 21.49 | 23.84 | 14.96 | 26.06 | 20.85 | 19.08 | 21.69 | 23.50 | 27.91 | 23.23 | 15.62 | 32.98 | 33.42 | 38.33 | 48.56 | 39.49 | 41.14 | 57.02 | 69.95 |
| Price to book ratio | 7.06 | 7.42 | 9.51 | 4.98 | 5.91 | 4.99 | 4.77 | 5.22 | 6.13 | 6.80 | 6.09 | 3.09 | 4.88 | 6.50 | 7.22 | 10.37 | 9.97 | 5.88 | 6.72 | 10.24 |
| Price to sales ratio | 6.42 | 5.51 | 8.02 | 5.28 | 9.42 | 6.85 | 5.47 | 6.10 | 7.20 | 7.66 | 6.93 | 4.08 | 7.56 | 9.36 | 9.94 | 14 | 13.13 | 9.68 | 11.65 | 16.38 |
| Price to cash flow ratio | 55.78 | 23.04 | 29.01 | 20.66 | 23.33 | 25.35 | 27.35 | 26.35 | 30.92 | 27.46 | 23.95 | 13.62 | 33.81 | 43.42 | 42.11 | 48.11 | 59.10 | 28.16 | 58.52 | 78.76 |
| Enterprise value | 2585Cr | 4130Cr | 8359Cr | 6272Cr | 8886Cr | 8959Cr | 9716Cr | 12639Cr | 17647Cr | 22990Cr | 25316Cr | 14896Cr | 26984Cr | 43807Cr | 51708Cr | 94215Cr | 114000Cr | 70805Cr | 87258Cr | 150000Cr |
| Enterprise value to EBITDA ratio | 22.26 | 17.32 | 19.91 | 12.19 | 21.76 | 18.22 | 14.16 | 15.58 | 17.46 | 19.79 | 17.70 | 9.91 | 22.10 | 24.09 | 28.81 | 33.45 | 29.46 | 29.44 | 37.45 | 49.19 |
| Debt to equity ratio | 0.44 | 0.29 | 0.10 | 0.04 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 22.30 | 42.47 | 49.77 | 39.63 | 24.68 | 25.90 | 27.15 | 25.99 | 28.31 | 26.37 | 28.91 | 21.98 | 15.55 | 21 | 19.30 | 23.90 | 28.16 | 14.89 | 12.15 | 15.35 |
Divis Laboratories Ltd Ratios
The Divis Laboratories Ltd Ratios page provides a complete fundamental analysis of Divis Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Divis Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Divis Laboratories Ltd (NSE: DIVISLAB, BSE: 532488) is currently trading at ₹10037.50, with a market capitalization of ₹266264.97Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Divis Laboratories Ltd remains a key stock for fundamental analysis using Divis Laboratories Ltd Ratios.
Divis Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Divis Laboratories Ltd P/E ratio currently stands at 69.95, making it one of the most tracked metrics in Divis Laboratories Ltd Ratios.
Historically, the Divis Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2025: 69.95
- 2024: 57.02
- 2023: 41.14
- 2022: 39.49
- 2021: 48.56
The rising Divis Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Divis Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 10.24.
Historical P/B trend:
- 2025: 10.24
- 2024: 6.72
- 2023: 5.88
- 2022: 9.97
Divis Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Divis Laboratories Ltd P/S ratio currently stands at 16.38, an important part of Divis Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 16.38
- 2024: 11.65
- 2023: 9.68
- 2022: 13.13
The rising Divis Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.
Divis Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Divis Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 78.76.
Historical Divis Laboratories Ltd Price to Cash Flow Ratio:
- 2025: 78.76
- 2024: 58.52
- 2023: 28.16
- 2022: 59.10
- 2021: 48.11
The rising Divis Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Divis Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Divis Laboratories Ltd EV currently stands at ₹150000Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 150000Cr
- 2024: 87258Cr
- 2023: 70805Cr
- 2022: 114000Cr
Divis Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Divis Laboratories Ltd EV/EBITDA ratio is currently 49.19, a key metric in Divis Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 49.19
- 2024: 37.45
- 2023: 29.44
- 2022: 29.46
Higher Divis Laboratories Ltd EV/EBITDA suggests premium valuation.
Divis Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Divis Laboratories Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0
- 2024: 0
- 2023: 0
- 2022: 0
Divis Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Divis Laboratories Ltd ROE currently stands at 15.35%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 15.35
- 2024: 12.15
- 2023: 14.89
- 2022: 28.16
Divis Laboratories Ltd maintains stable profitability levels.
Divis Laboratories Ltd Ratios Analysis Summary
The Divis Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Divis Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Divis Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
